GLP-1 drugs may reduce the risk of cancer progressing, study suggests - NBC News
GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting. The list of health benefits tied to the diabetes and weight loss drugs has been growing — approvals have been expanded to reduce risk of heart disease (Wegovy), to prevent worsening kidney disease (Ozempic) and to treat obstructive sleep apnea (Zepbound) — and researchers continue to look for other possibilities.